Compare Davita Inc (DVA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Shell PLC — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Shell PLC trades at $84.86 (market cap $230.24B). The key difference: Shell PLC is far larger — about 15.4× Davita Inc's market cap, and Shell PLC pays a 3.7% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SHEL | |
|---|---|---|
Market Cap | $14.92B | $230.24B |
Sector | Health | Energy |
52-Week High | $235.71 | $94.15 |
52-Week Low | $103.87 | $70.28 |
Enterprise Value | $27.47B | $282.77B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Shell (SHEL) trades at $83.98, up 2.13% in the last session, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations at $2.44 EPS, while Q2 2026 is projected at $2.88. Valuation metrics appear attractive with a P/E of 13.08 and P/S of 0.92. News highlights include the ARC Resources acquisition approval and Venezuela gas field developments, indicating strategic growth initiatives.
The outlook for SHEL is positive, supported by robust cash flows, a 69% buy rating from analysts, and a consensus price target of $122.20. Risks include declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and geopolitical disruptions in Middle East production. Investors may find value in its dividend yield and LNG market exposure, though macroeconomic volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
